澳门新葡官网进入(China)APP网站-BinG百科

1 / 3

About Ribo

Established in 2007, Suzhou Ribo Life Science Co., Ltd. (Ribo) is a clinical stage company devoted to the development of innovative RNAi technologies and oligonucleotide therapeuticsto address unmet clinical needs in the world. 

Based on its cutting edge RNAi technologies, Ribo has established oligonucleotide therapeutic platform that vertically integrates the complete set of technologies to support the full life cycle of oligonucleotide therapeutics from early R&D to commercialization.

Technological Innovations

Ribo strives innovation of key technologies for development of oligonucleotide therapeutics. Our liver-targeting delivery technology and second-generation modification chemistry have been fully developed and supported several products entering clinical phase of development. Moreover, we have made substantial advancement in developing extrahepatic delivery technologies, and we also made commendable achievement in additional fronts, including our third-generation modification chemistry, multi-target siRNA technology, and novel synthetic methodologies.

siRNA delivery technology platform

Oligonucleotide modification for enhanced stability platform

CMC Development of Oligonucleotide platform

Oligonucleotide sequence design and high-throughput screening platform

Pipeline

Through our innovation, Ribo has built a robust pipeline of oligonucleotide therapeutics that focus on differentiated drug product development with the potential to be First-In-Class or Best-In-Class. Our pipeline covers multiple therapeutic areas, including cardiovascular and metabolic disorders, liver diseases, rare diseases, and ocular diseases.

RBD7022

Hyperlipidemia

RBD5044

Hyperlipidemia

RBD4059

Thromboembolism

RBD1016

HBV

RBD7007

CMD

RBD8088

Glioma